Abstract
Positron Emission Tomography (PET) is undergoing a profound transformation. Driven by the convergence of highly sensitive long-axial field-of-view (LAFOV) total-body PET systems and an expanding portfolio of targeted radiopharmaceuticals, PET is progressively evolving beyond its traditional role in oncologic diagnosis and staging. Ultra-sensitive scanners enable whole-body imaging with markedly reduced radiotracer doses, rapid acquisition times, and true dynamic multiparametric imaging across all organs simultaneously. In parallel, molecularly targeted radioligands support tumour phenotyping, theranostic applications, and personalized dosimetry. Together, these advances position PET as a systemic imaging platform capable of interrogating whole-body tumour biology, guiding precision therapies, and potentially enabling early detection or surveillance strategies in selected high-risk populations. This narrative review summarizes the technological foundations of total-body PET, reviews current clinical and translational applications, discusses opportunities and limitations for early detection and surveillance, and outlines a research and implementation roadmap to responsibly translate this paradigm into clinical oncology.